

SRES 97

A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

Congress: 113 (2013–2015, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 15, 2013

Current Status: Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced:

Latest Action: Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654) (Apr 15, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/senate-resolution/97>

Sponsor

Name: Sen. Coburn, Tom [R-OK]

Party: Republican • **State:** OK • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. McConnell, Mitch [R-KY]	R · KY		Apr 15, 2013
Sen. Schumer, Charles E. [D-NY]	D · NY		Apr 15, 2013
Sen. Alexander, Lamar [R-TN]	R · TN		Apr 16, 2013

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 15, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 HRES 161	Related bill	Apr 19, 2013: Referred to the Subcommittee on Health.

Summary (as of Apr 15, 2013)

Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

Actions Timeline

- **Apr 15, 2013:** Introduced in Senate
- **Apr 15, 2013:** Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)